Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Harpoon Therapeutics Inc

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Harpoon Therapeutics, Inc. (NasdaqCM: HARP) to Merck & Co., Inc. (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Harpoon will receive $23.00 in cash for each share of Harpoon that they own. KSF is seeking to determine whether this consideration and the process that led to it are a.

HARPOON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Harpoon Therapeutics, Inc. - HARP

Agenus

Bristol-Myers

Compugen

GlaxoSmithKline

iTeos Therapeutics, Inc.

Novartis

Pfizer

Arcus Biosciences

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

VanEck Vectors Biotech ETF

Virtus LifeSci Biotech Products ETF

iShares Nasdaq Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

Johnson & Johnson

SPDR S&P Biotech ETF

The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.

Biotech ETFs Stage Solid Comeback at the Start of 2024

Merck's (MRK) Harpoon buyout is expected to strengthen its oncology pipeline by adding the latter's lead pipeline candidate, HPN328, a T cell engager being studied for SCLC and neuroendocrine tumors.

Merck (MRK) to Strengthen Cancer Pipeline With Harpoon Buyout

Merck & Co., Inc. (MRK) Presents at JPMorgan 42nd Annual Healthcare Conference (Transcript)

Apple

AbbVie

Advanced Micro Devices

Amgen

Amazon

ASML Hld

Broadcom

Blackrock Inc

FactSet Research Systems

Alphabet

Home Depot

Lowe's

Mastercard

Altria

MSCI

Microsoft

NVIDIA

Realty Income Corp

Prologis

Invesco QQQ

Schwab US Dividend Equity ETF

SPDR S&P 500 ETF Trust

Tesla

How To Build A Dividend Growth Portfolio As A 'Young Investor' With $100,000

The shares of Merck & Co Inc (NYSE:MRK) are already 7.3% higher since the start of the year, and earlier hit a six-month high of $117.89 before turning lower.

Merck Stock's Rally Could Extend to Record Highs

Shares of Harpoon Therapeutics Inc. (HARP) more than doubled Monday after Merck & Co. (MRK) agreed to buy the cancer drug researcher for about $680 million.

Merck Buys Harpoon Therapeutics To Expand Its Oncology Portfolio

Merck (MRK) begins global pivotal studies on bomedemstat, nemtabrutinib, MK-2870 and MK-5684.

Merck (MRK) Begins Pivotal Studies on Four Cancer Candidates

Merck and Johnson & Johnson are paying big premiums to acquire companies with promising biotech targets.

Merck and J&J's Biotech Deals Are More Good News for a Troubled Sector

Merck stock is shrugging off seven months of underperformance, shooting more than 7% higher in the first week of 2024.

Merck Stock Has Been A Laggard For Seven Months. Is It Staging A Comeback?

Boston Scientific

J&J, Merck and Boston Scientific kicked off the year's biggest medical conference with a trio of takeovers. AMAM stock and HARP stock soared.

J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value

Merck is a pharmaceutical giant whose medications and vaccines play key roles in the fight against viruses, cancer, and cardiovascular diseases. On October 26, 2023, Merck published results for the 3rd quarter of 2023, which left mixed feelings. The exclusivity of most of the company's medications and vaccines is set to expire within the next five years.

Merck's Soaring Stock: Examining The Euphoria Amidst Potential Pitfalls

Merck has struck a deal to buy clinical-stage immunotherapy company Harpoon Therapeutics for about $680 million.

Merck to Buy Harpoon Therapeutics for $680 Million

Merck & Co said on Monday it would buy cancer drug developer Harpoon Therapeutics for about $680 million, reinforcing its oncology portfolio with immunotherapies.

Merck to buy Harpoon Therapeutics for $680 million

RAHWAY, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Harpoon Therapeutics, Inc. (Nasdaq: HARP) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million. “At Merck, we continue to enhance our oncology pipeline through strategic acquisitions that compl.

Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline

Merck & Co Inc (NYSE:MRK) is close to acquiring Harpoon Therapeutics Inc, a cancer drug developer, for about $700 million to bolster its oncology portfolio. The proposed deal, which could value Harpoon at $23 per share, aligns with Merck's strategy to seek new growth opportunities as its top-selling cancer drug Keytruda faces future pricing pressures.

Merck close to acquiring cancer specialist Harpoon Therapeutics

Merck MRK, +0.18% is in talks to buy cancer drugmaker Harpoon Therapeutics HARP, -1.49% for about $700 million, or $23 per share, Bloomberg News reported, citing people familiar with the matter. Merck didn't comment to Bloomberg, the report said, while Harpoon didn't respond.

Merck reportedly in talks to buy drugmaker for more than double Friday's price

Merck & Co is in advanced talks to buy cancer drugmaker Harpoon Therapeutics Inc for around $700 million, Bloomberg News reported on Sunday, citing people familiar with the matter.

Merck in talks to buy Harpoon Therapeutics for around $700 mln - Bloomberg News

Gilead Sciences

Sanofi

The Pharmaceutical segment offers human health pharmaceutical products in: Oncology, Hospital acute care Immunology Neuroscience Virology Cardiovascular and diabetes Vaccine products, such as preventive pediatric, adolescent, and adult vaccines The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.

7 Rock-Solid Healthcare Dividend Stocks to Buy in January

Allstate

Incyte

Eli Lilly

Moderna

Viatris

The calendar just flipped to 2024 — and investors already have their favorite S&P 500 stocks. And none of them are the Big Tech giants that dominated.

7 Stocks Are Taking Off Already — And The Year Just Started

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline.

Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline

Merck & Co., Inc. (MRK) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript)

Merck & Co's Chief Executive Officer Robert Davis said on Thursday the company is seeking GLP-1 treatments with benefits beyond weight loss.

Merck seeks GLP-1 drugs with benefits beyond weight loss - CEO

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced a licensing agreement with Inspirna, Inc. (New York, NY) for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8, and SLC6A8-targeting follow-on compounds. Ompenaclid is currently being evaluated in a Phase II study for the second-line treatment of RAS-mutated (RASmut) advanced or metastatic colorectal cancer (mCRC). “Over the past decade, the treatmen.

News for Merck Stock (MRK)